Pfizer halts some MMPI trials

PFE's decision to end two Phase III trials of its prinomastat follows a series of disappointments in the matrix metalloproteinase inhibitor (MMPI) space. Bayer (DAX:BAYG) has dropped BAY 12-9566 in os...